Archive · 2 Jun 2025
Deepak Nitrite Stock Receives Mixed Ratings From Analysts
Deepak Nitrite, a chemical company, is facing mixed reviews from financial analysts.
Some firms, like Morgan Stanley, suggest the stock could go up, while others, like Motilal Oswal, think it's overpriced and will go down.
The company had a good quarter with high sales and profit margins.
Deepak Nitrite is expanding and has projects planned, but some are delayed.
Different firms have different ratings and price targets for the stock, showing varied expectations for its future performance.
The management is positive about future growth.
Motilal Oswal downgraded Deepak Nitrite to 'Sell' due to valuation concerns.
Morgan Stanley has an 'Overweight' rating with a price target of ₹2,421.
Nuvama retained a 'Hold' rating, increasing the price target to ₹2,073.
Deepak Nitrite shares increased over 6% on Thursday following a strong Q4.
The company is expanding, with projects worth ₹2,200 crore scheduled for FY26, though some delays exist.
- Who
- Various brokerage firms such as Motilal Oswal, Morgan Stanley, Nuvama Institutional Equities, and Emkay Global are analyzing Deepak Nitrite.
- What
- Deepak Nitrite's stock is being analyzed by various brokerage firms after a better-than-expected fourth quarter.
- When
- Analysis occurred after the company reported its fourth quarter results.
- Where
- The analysis is based on the company's performance and future projections.
- Why
- Motilal Oswal cited expensive valuations as the reason for the downgrade.
Bearish View
Bullish View
Valuation
Bearish View
Motilal Oswal cited expensive valuations for the downgrade and Emkay Global has retained a Reduce rating.
Bullish View
Morgan Stanley believes the stock has potential upside. Nuvama also increased the price target.
Future Performance
Bearish View
Motilal Oswal expects potential downward revisions in estimates for FY26 and FY27.
Bullish View
The company's management is bullish on growth prospects for FY26.
- Motilal Oswal Price Target
- ₹1,650
- Morgan Stanley Price Target
- ₹2,421
- Nuvama Price Target
- ₹2,073
- Emkay Global Price Target
- ₹2,000
- Margin expansion in Q4
- 150 bps